A systematic analysis of commonly used antibodies in cancer diagnostics
A systematic analysis of commonly used antibodies in cancer diagnostics
复制标题
DOI：
10.1111/his.12255
复制
发表时间：
2014-01-01
期刊：
影响因子：
6.4
通讯作者：
Ponten, Fredrik
中科院分区：
文献类型：
--
作者：
Gremel, Gabriela;Bergman, Julia;Ponten, Fredrik
免疫组化在肿瘤鉴别诊断中起着关键作用。从转移标本中鉴别原发性肿瘤仍然是一个重大挑战，尽管有越来越多的抗体可用。本研究的目的是提供基于证据的数据的诊断能力的抗体经常用于临床鉴别diagnostics.Methods和resultsA组织微阵列队列包括940个肿瘤样本，其中502个是转移性病变，代表肿瘤从18个不同的器官和四个非本地化的癌症类型，使用免疫组织化学与临床鉴别诊断中使用的27种成熟的抗体进行分析。很少有抗体，如前列腺特异性抗原和甲状腺球蛋白，显示癌症类型相关的敏感性和特异性超过95%。大多数抗体对确定的癌症类型显示出低程度的灵敏度和特异性。抗体的组合提供了有限的附加值为癌症types.ConclusionsThe的结果，从分析27个诊断抗体的连续部分940定义的肿瘤提供了一个独特的数据库，可以使临床免疫组化的更优化的使用。我们的研究结果突出了免疫组化的好处和对新标记物的未满足的需求，以改善癌症的鉴别诊断。
AimsImmunohistochemistry plays a pivotal role in cancer differential diagnostics. To identify the primary tumour from a metastasis specimen remains a significant challenge, despite the availability of an increasing number of antibodies. The aim of the present study was to provide evidence-based data on the diagnostic power of antibodies used frequently for clinical differential diagnostics.Methods and resultsA tissue microarray cohort comprising 940 tumour samples, of which 502 were metastatic lesions, representing tumours from 18 different organs and four non-localized cancer types, was analysed using immunohistochemistry with 27 well-established antibodies used in clinical differential diagnostics. Few antibodies, e.g. prostate-specific antigen and thyroglobulin, showed a cancer type-related sensitivity and specificity of more than 95%. A majority of the antibodies showed a low degree of sensitivity and specificity for defined cancer types. Combinations of antibodies provided limited added value for differential diagnostics of cancer types.ConclusionsThe results from analysing 27 diagnostic antibodies on consecutive sections of 940 defined tumours provide a unique repository of data that can empower a more optimal use of clinical immunohistochemistry. Our results highlight the benefit of immunohistochemistry and the unmet need for novel markers to improve differential diagnostics of cancer.